Evidence map›Paper›PMID 35905044›Full record

ArticlePloS one2022

Mutations in SORL1 and MTHFDL1 possibly contribute to the development of Alzheimer's disease in a multigenerational Colombian Family.

Johanna Alexandra Tejada Moreno, Andrés Villegas Lanau, Lucia Madrigal Zapata, Ana Yulied Baena Pineda, Juan Velez Hernandez, Omer Campo Nieto, Alejandro Soto Ospina, Pedronel Araque Marín, Lavanya Rishishwar, Emily T Norris and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Influence ofAnnals of medicine · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Transethnic analysis identifies SORL1 variants and haplotypes protective against Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Johanna Alexandra Tejada MorenoMolecular Genetics Research Group, University of Antioquia, Medellin, Colombia.ORCID 0000-0002-8395-0233
Andrés Villegas LanauNeuroscience Research Group, University of Antioquia, Medellin, Colombia.
Lucia Madrigal ZapataNeuroscience Research Group, University of Antioquia, Medellin, Colombia.
Ana Yulied Baena PinedaNeuroscience Research Group, University of Antioquia, Medellin, Colombia.
Juan Velez HernandezNeuroscience Research Group, University of Antioquia, Medellin, Colombia.
Omer Campo NietoMolecular Genetics Research Group, University of Antioquia, Medellin, Colombia.
Alejandro Soto OspinaMolecular Genetics Research Group, University of Antioquia, Medellin, Colombia.
Pedronel Araque MarínResearch and Innovation Group in Chemical Formulations, EIA University, Medellin, Colombia.
Lavanya RishishwarIHRC-Georgia Tech Applied Bioinformatics Laboratory, Atlanta, Georgia, United States of America.
Emily T NorrisIHRC-Georgia Tech Applied Bioinformatics Laboratory, Atlanta, Georgia, United States of America.
Aroon T ChandeIHRC-Georgia Tech Applied Bioinformatics Laboratory, Atlanta, Georgia, United States of America.ORCID 0000-0001-5260-3135
I King JordanIHRC-Georgia Tech Applied Bioinformatics Laboratory, Atlanta, Georgia, United States of America.
Gabriel Bedoya BerrioMolecular Genetics Research Group, University of Antioquia, Medellin, Colombia.
Universidad de Antioquia · COGeorgia Institute of Technology · USEIA University · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common cause of dementia in the elderly, affecting over 50 million people worldwide in 2020 and this number will triple to 152 million by 2050. Much of the increase will be in developing countries like Colombia. In familial forms, highly penetrant mutations have been identified in three genes, APP, PSEN1, and PSEN2, supporting a role for amyloid-β peptide. In sporadic forms, more than 30 risk genes involved in the lipid metabolism, the immune system, and synaptic functioning mechanisms. We used whole-exome sequencing (WES) to evaluate a family of 97 members, spanning three generations, with a familiar AD, and without mutations in APP, PSEN1, or PSEN2. We sequenced two affected and one unaffected member with the aim of identifying genetic variants that could explain the presence of the disease in the family and the candidate variants were validated in eleven members. We also built a structural model to try to determine the effect on protein function. WES analysis identified two rare variants in SORL1 and MTHFD1L genes segregating in the family with other potential risk variants in APOE, ABCA7, and CHAT, suggesting an oligogenic inheritance. Additionally, the structural 3D models of SORL1 and MTHFD1L variants shows that these variants produce polarity changes that favor hydrophobic interactions, resulting in local structural changes that could affect the protein function and may contribute to the development of the disease in this family.

Indexed as

Alzheimer DiseaseAgedAmyloid beta-Protein PrecursorColombiaExome SequencingGenetic Predisposition to DiseaseHumansLDL-Receptor Related ProteinsMembrane Transport ProteinsMethylenetetrahydrofolate Dehydrogenase (NADP)Minor Histocompatibility AntigensMutationPresenilin-1Amyloid beta-Protein PrecursorLDL-Receptor Related ProteinsMembrane Transport ProteinsMethylenetetrahydrofolate Dehydrogenase (NADP)Minor Histocompatibility AntigensMTHFD1 protein, humanPresenilin-1SORL1 protein, human

Identifiers

PMID35905044
PMCPMC9337667
OpenAlexW4288695362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.